Biotechnology

Praxis Precision Medicines

Multiple Investment Firms Issue or Maintain Buy/Sell Ratings on Praxis Precision Medicines (PRAX)

Praxis Precision Medicines: Vormatrigine Epilepsy Trial Fails, POWER2 Enrollment Paused

Praxis Precision Medicines Reports Q1 2026 Financial Results, Net Loss of $92.6 Million

Praxis Precision Medicines NDA Accepted by FDA

Praxis Precision Medicines released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual EPS USD -3.2046 (forecast USD -3.5687)

Praxis Precision Medicines Releases Corporate Presentation on CNS Product Portfolio

Praxis Precision Announces Q1 Operating Expenses and Net Income

Praxis Precision Medicines to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast EPS USD -3.5687

Praxis Precision Medicines’ New Drug Application Accepted by FDA

Praxis Precision Medicines Announces Positive Results for Idiopathic Tremor Drug in Phase III Trial

Praxis Precision Medicines Shares Rise as Elsunersen Trial Results Prove Positive

Praxis's New Drug Application Receives Priority Review by FDA

Driehaus Capital Management Increases Holdings in Praxis Precision Medicines

Praxis Precision Medicines reports larger net losses for Q4 and full-year 2025

Praxis Precision Medicines released FY2025 annual earnings on February 19 Pre-Market EST, actual revenue USD 0 (forecast USD 239.01 K), actual EPS USD -13.4757 (forecast USD -13.078)

Praxis Precision Medicines released FY2025 Q4 earnings on February 19 Pre-Market EST, actual revenue USD 0 (forecast USD 256.09 K), actual EPS USD 0 (forecast USD -3.1009)

Praxis Precision submits new drug applications and announces top-line results

Praxis Precision reports Q4 financial data

Praxis Precision Medicines to Release FY2025 Q4 Earnings on February 19, Pre-Market EST; Forecast Revenue USD 256.09K, EPS USD -3.1009

Praxis Precision Medicines Receives 'Modest Buy' Consensus Rating With Target Price of $436.67

VS MEDIA

Big Tree Cloud

Tianci

Fold

Pop Culture

ChowChow Cloud

Autozi Internet Tech Global

Green Circle Decarbonize Tech

Hitek Global Inc.

EWTX

JBIO

PRAX

IDYA

Wedbush adjusted analyst ratings for four biotech firms: Praxis (PRAX) price target cut to $162 after POWER1 trial miss; IDEAYA (IDYA) and Edgewise (EWTX) retain Outperform ratings with targets of $58 and $52 respectively, following positive OptimUM-02 data and a $1.55B Servier deal; Jade Biosciences (JBIO) target raised to $45 on strong JADE101 Phase 1 data.

rttnews

Edgewise Therapeutics

Jade Biosciences

Ideaya Biosciences

Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE

INTU

CRDO

FULC

CRWD

Wall Street analysts updated ratings and price targets for several stocks. Baird raised CrowdStrike's target to $490; Goldman Sachs raised HP's to $19 but lowered Intuit's to $276 with a downgrade. HC Wainwright downgraded Fulcrum Therapeutics to Neutral with a $3 target. Evercore ISI upgraded Guardant Health to Outperform, raising its target to $160. Needham increased Credo Technology's target to $275. BTIG slightly cut Praxis Precision Medicines' target, while BofA downgraded Nu Holdings to Underperform with a $10 target.

benzinga_article

Intuit

Guardant Health

Credo Tech

NU Holdings

Fulcrum Therapeutics

CrowdStrike

Genasys

CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday

Truist Financial analyst Danielle Brill maintained a Buy rating on Praxis Precision Medicines (PRAX) with a $616 price target. Deutsche Bank's David Hoang also issued a Buy rating today, while Wedbush maintained a Sell rating on the stock.

Praxis Precision Medicines(PRAX.US)

Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE

CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday

Praxis Precision Medicines (PRAX) Gets a Buy from Truist Financial